Excalibur Management Corp Purchases 6,199 Shares of Bristol-Myers Squibb (NYSE:BMY)

Excalibur Management Corp increased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 24.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,641 shares of the biopharmaceutical company’s stock after buying an additional 6,199 shares during the period. Excalibur Management Corp’s holdings in Bristol-Myers Squibb were worth $1,314,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of BMY. Gryphon Financial Partners LLC increased its stake in Bristol-Myers Squibb by 23.5% in the fourth quarter. Gryphon Financial Partners LLC now owns 5,235 shares of the biopharmaceutical company’s stock valued at $280,000 after purchasing an additional 995 shares in the last quarter. Gladstone Institutional Advisory LLC increased its stake in Bristol-Myers Squibb by 19.8% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 62,786 shares of the biopharmaceutical company’s stock valued at $3,222,000 after purchasing an additional 10,373 shares in the last quarter. Thoroughbred Financial Services LLC increased its stake in Bristol-Myers Squibb by 4.8% in the fourth quarter. Thoroughbred Financial Services LLC now owns 23,095 shares of the biopharmaceutical company’s stock valued at $1,185,000 after purchasing an additional 1,065 shares in the last quarter. Clearbridge Investments LLC increased its stake in Bristol-Myers Squibb by 12.0% in the fourth quarter. Clearbridge Investments LLC now owns 125,980 shares of the biopharmaceutical company’s stock valued at $6,464,000 after purchasing an additional 13,534 shares in the last quarter. Finally, Sachetta LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at $57,000. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Jefferies Financial Group boosted their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. Barclays boosted their target price on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a research report on Thursday, August 22nd. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $50.00 target price on shares of Bristol-Myers Squibb in a research report on Monday. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and an average price target of $55.00.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY opened at $50.00 on Tuesday. The company has a market capitalization of $101.36 billion, a P/E ratio of -16.13, a P/E/G ratio of 12.59 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $59.46. The firm’s 50 day simple moving average is $46.99 and its two-hundred day simple moving average is $46.47.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. The business had revenue of $12.20 billion for the quarter, compared to analysts’ expectations of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The business’s revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.75 earnings per share. Research analysts expect that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.80%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.